[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Volume 22, Issue 2 (4-2024) ::
Int J Radiat Res 2024, 22(2): 315-319 Back to browse issues page
Diagnostic value of joint detection of serum tumor markers in different pathological types of lung cancer
W. Liu , D. Zang
Department of Clinical Laboratory, Beijing Hospital of Integrated Chinese & Western Medicine, Beijing 100039, China , lww16032810@163.com
Abstract:   (481 Views)
Background: To evaluate the diagnostic potential of joint testing of serum tumor markers containing cytokeratin fragment antigen 21-1 (CYFRA21-1), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA) as well as neuron-specific enolase (NSE) in a variety oflung cancer (LC). Materials and Methods: The LC group comprised 150 LC patients who were diagnosed for the first time and were not treated. During the same period, 120 patients harbored benign lung diseases and 120 healthy subjects were respectively designated as the benign group and control group. Immunochemiluminescence assay was implemented to detect tumor markers in serum from three groups and different types of LC. Results: Levels of four serum tumor markers in LC group were elevated relative to control group. CYFRA21-1 level in lung squamous cell carcinoma (LSCC) group was elevated compared to lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) groups. ProGRP and NSE levels in SCLC group increased compared to LSCC and LUAD groups. CEA level in LUAD group was higher compared to LSCC and SCLC groups. The highest positive rate of LSCC was CYFRA21-1, the highest positive rate of LUAD was CEA and the highest positive rates of SCLC were ProGRP and NSE. In terms of single tumor marker detection, CYFRA21-1 possessed the best diagnostic efficiency for LSCC, CEA possessed the best diagnostic efficiency for LUAD, NSE and ProGRP possessed the best diagnostic efficiency for SCLC, respectively. Conclusion: The individual determination of CYFRA21-1, ProGRP, CEA, and NSE has certain clinical application value for the pathological classification of LC.
Keywords: Lung cancer, tumor markers, diagnosis.
Full-Text [PDF 786 kb]   (150 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. 1. Bade BC and Dela Cruz CS (2020) Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med, 41(1): 1-24. [DOI:10.1016/j.ccm.2019.10.001]
2. Nasim F, Sabath BF, Eapen GA (2019) Lung Cancer. Med Clin North Am, 103(3): 463-473. [DOI:10.1016/j.mcna.2018.12.006]
3. de Sousa VML and Carvalho L (2018) Heterogeneity in Lung Cancer. Pathobiology, 85(1-2): 96-107. [DOI:10.1159/000487440]
4. Jones GS and Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond), 18(2): s41-s46. [DOI:10.7861/clinmedicine.18-2-s41]
5. Berzenji L and Van Schil PE (2019) Surgery or stereotactic body radiotherapy for early-stage lung cancer: two sides of the same coin? Eur Respir J, 53(6). [DOI:10.1183/13993003.00711-2019]
6. Vodicka J, Pesta M, Kulda V, et al. (2020) Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure. Cells, 9(12). [DOI:10.3390/cells9122611]
7. Nooreldeen R and Bach H (2021) Current and future development in lung cancer diagnosis. Int J Mol Sci, 22(16). [DOI:10.3390/ijms22168661]
8. Faria SC, Sagebiel T, Patnana M, et al.(2019) Tumor markers: myths and facts unfolded. Abdom Radiol (NY), 44(4): 1575-1600. [DOI:10.1007/s00261-018-1845-0]
9. Dong X, Men X, Zhang W, Lei P (2014) Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer, 51(3): e72-6. [DOI:10.4103/0019-509X.154049]
10. Dal Bello MG, Filiberti RA Alama A, et al. (2019) The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med, 17(1): 74. [DOI:10.1186/s12967-019-1828-0]
11. Wojcik E and Kulpa JK (2017) Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response. Lung Cancer (Auckl), 8: 231-240. [DOI:10.2147/LCTT.S149516]
12. Jiang ZF, Wang M, Xu JL, (2018) Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci, 194: 1-6. [DOI:10.1016/j.lfs.2017.12.020]
13. Wu F, Wang L, Zhou C, (2019) Lung cancer in China: current and prospect. Curr Opin Oncol, 33(1): 40-46. [DOI:10.1097/CCO.0000000000000703]
14. Fu L, Wang R, Yin L, et al. (2019) CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis. Int J Biol Markers, 34(3): 251-261. [DOI:10.1177/1724600819868234]
15. Grunnet M and Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer, 76(2): 138-43. [DOI:10.1016/j.lungcan.2011.11.012]
16. Dong A, Zhang J, Chen X, et al. (2019) Diagnostic value of ProGRP for small cell lung cancer in different stages. J Thorac Dis, 11(4): 1182-1189. [DOI:10.21037/jtd.2019.04.29]
17. Zhou W, YangY, Wang Z, (2021) Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on lung cancer patients. J Healthc Eng, 2021: 6929971. [DOI:10.1155/2021/6929971]
18. Zhang L, Liu D, Li L, et al. (2017) The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer, 17(1): 96. [DOI:10.1186/s12885-017-3070-6]
19. Zhang HQ, Wang RB, Yan HJ, et al. (2012) Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. Asian Pac J Cancer Prev, 13(1): 199-203. [DOI:10.7314/APJCP.2012.13.1.199]
20. Kuang LI, Song WJ, Qing HM, et al. (2015) CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis. Genet Mol Res, 14(2): 3921-31. [DOI:10.4238/2015.April.27.6]
21. Hanada S, Nishiyama N, Mizuguchi S, et al. (2013) Clinicopathological significance of combined analysis of cytokeratin19 expression and preoperative serum CYFRA21-1 levels in human lung squamous cell carcinoma. Osaka City Med J, 59(1): 35-44.
22. Lu L, Zha Z, Zhang P, et al. (2021) NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process. Int J Med Sci, 18(16): 3768-3779. [DOI:10.7150/ijms.58415]
23. Lyubimova NV, Kuz'minov AE, Markovich AA, et al. (2022) Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer. Bull Exp Biol Med, 173(2): 257-260. [DOI:10.1007/s10517-022-05529-9]
24. Molina R, Filella X, Augé JM (2004) ProGRP: a new biomarker for small cell lung cancer. Clin Biochem, 37(7): 505-11. [DOI:10.1016/j.clinbiochem.2004.05.007]
25. Wójcik E, Kulpa JK, Sas-Korczyńska B, et al. (2008) ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res, 28(5b): 3027-33.
26. Lakemeyer L, Sander S, Wittau M, et al. (2021) Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer. Diseases, 9(1): 21. [DOI:10.3390/diseases9010021]
27. Hall C, Clarke L, Pal A, et al. (2019) A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol, 35(6): 294-305. [DOI:10.3393/ac.2019.11.13]
28. Lee TH, Kim JS, Baek SJ, et al. (2023) Diagnostic accuracy of carcinoembryonic antigen (CEA) in detecting colorectal cancer recurrence depending on its preoperative level. J Gastrointest Surg, 27(8): 1694-1701. [DOI:10.1007/s11605-023-05761-2]
29. Hao C, Zhang G, Zhang L (2019) Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci, 162: 213-227. [DOI:10.1016/bs.pmbts.2018.12.011]
30. Cheng C, Yang Y, Yang W, et al. (2022) The diagnostic value of CEA for lung cancer-related malignant pleural effusion in China: a meta-analysis. Expert Rev Respir Med, 16(1): 99-108. [DOI:10.1080/17476348.2021.1941885]
31. Hiraoka K and Horie A (1988) Immunohistochemical study of carcinoembryonic antigen (CEA) in lung carcinoma by five monoclonal antibodies. J uoeh, 10(3): 237-46. [DOI:10.7888/juoeh.10.237]
32. Wang L, Wang D, Zheng G, et al. (2016) Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer. Int J Biol Markers, 31(1): e80-7. [DOI:10.5301/jbm.5000177]
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Liu W, Zang D. Diagnostic value of joint detection of serum tumor markers in different pathological types of lung cancer. Int J Radiat Res 2024; 22 (2) :315-319
URL: http://ijrr.com/article-1-5415-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (4-2024) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4660